Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033987 | 0.88 | SMN1; SMN2 (0.75) | SMN1; SMN2ALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL15183921 | 0.88 | PDE7A (0.71) | SMN1; SMN2ALDH1A1MAPTKMT2APDE7A | |
| SCHEMBL15179080 | 0.86 | ALDH1A1 (0.70) | SMN1; SMN2ALDH1A1MAPTKMT2APDE7A | |
| SCHEMBL18239985 | 0.78 | PDE7A (1.00) | SMN1; SMN2ALDH1A1MAPTKMT2APDE7A | |
| SCHEMBL19851100 | 0.75 | TSHR (0.66) | SMN1; SMN2ALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL11435540 | 0.73 | L3MBTL1 (0.71) | SMN1; SMN2ALDH1A1MAPTKMT2APDE7A | |
| SCHEMBL18239971 | 0.73 | PDE7A (1.00) | SMN1; SMN2ALDH1A1MAPTKMT2APDE7A | |
| SCHEMBL1129585 | 0.73 | PDE7A (0.73) | SMN1; SMN2ALDH1A1MAPTPDE7ATP53 | |
| Methaqualone SCHEMBL29064194 | 0.72 | ALDH1A1 (0.94) | SMN1; SMN2ALDH1A1KMT2ANPSR1PDE7A | |
| SCHEMBL19403443 | 0.72 | PSMD14 (0.75) | SMN1; SMN2ALDH1A1MAPTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888332-B2 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-7414037-B2 | cystic fibrosis transmembrane conductance regulator protein inhibitor; 2-naphthalenylamino-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene][3-[4-(3-(PEG)n-thioureido)diphenyl)-thioureido]propanedioic acid dihydrazide (MalH-(PEG)nB); cystic fibrosis with forms of male infertility, secretory diarrhea | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, ABCC5, SLC9A5 | SMN1; SMN2 3881/4885ALDH1A1 1636/4885MAPT 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.